The use of RNA-based 5'-aminolevulinate synthase 2 biomarkers in dried blood spots to detect recombinant human erythropoietin microdoses. by Loria, F. et al.
S P E C I A L I S S U E - R E S E A R CH A R T I C L E
The use of RNA-based 5'-aminolevulinate synthase
2 biomarkers in dried blood spots to detect recombinant
human erythropoietin microdoses
Francesco Loria1 | Holly D. Cox2 | Sven C. Voss3 | Angela Rocca1 |
Geoffrey D. Miller2 | Nathan Townsend4 | Costas Georgakopoulos3 |
Daniel Eichner2 | Tiia Kuuranne1 | Nicolas Leuenberger1
1Swiss Laboratory for Doping Analyses,
University Center of Legal Medicine, Lausanne
and Geneva, Lausanne University Hospital and
University of Lausanne, Lausanne, Switzerland
2Sports Medicine Research and Testing
Laboratory, Salt Lake City, Utah, USA
3Anti-Doping Lab Qatar, Doha, Qatar
4Athlete Health and Performance Centre,
Aspetar Orthopaedic and Sports Medicine
Hospital Doha, Doha, Qatar
Correspondence
Nicolas Leuenberger, Swiss Laboratory for
Doping Analyses, University Center of Legal
Medicine, Lausanne and Geneva, Lausanne
University Hospital and University of




Partnership for Clean Competition
Abstract
The hematological module of the Athlete Biological Passport (ABP) is used for indi-
rect detection of blood manipulations; however, the use of this method to detect
doping, such as with microdoses of recombinant human erythropoietin (rhEPO), is
problematic. For this reason, the sensitivity of ABP must be enhanced by
implementing novel biomarkers. Here, we show that 5'-aminolevulinate synthase
2 (ALAS2) mRNAs are useful transcriptomic biomarkers to improve the indirect detec-
tion of rhEPO microdosing. Moreover, the sensitivity was sufficient to distinguish
rhEPO administration from exposure to hypoxic conditions. Levels of mRNAs
encoding carbonate anhydrase 1 (CA1) and solute carrier family 4 member 1 (SLC4A1)
RNA, as well as the linear (L) and linear + circular (LC) forms of ALAS2 mRNA, were
monitored for 16 days after rhEPO microdosing and during exposure to hypoxic con-
ditions. ALAS2 mRNAs increased by 300% compared with the baseline values after
rhEPO microdosing. Moreover, ALAS2 mRNAs were not significantly increased under
hypoxic conditions. By contrast, CA1 mRNA was increased after both rhEPO micro-
dosing and hypoxia, whereas SLC4A1 mRNA did not significantly increase under
either condition. Furthermore, the analyses described here were performed using
dried blood spots (DBSs), which provide advantages in terms of the sample collection,
transport, and storage logistics. This study demonstrates that ALAS2 mRNA levels are
sensitive and specific transcriptomic biomarkers for the detection of rhEPO micro-
dosing using the hematological module of the ABP, and this method is compatible
with the use of DBSs for anti-doping analyses.
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1 | INTRODUCTION
Indirect detection of blood manipulations using the hematological
module of the Athlete Biological Passport (ABP) can be challenging,
for example, in unmasking doping with microdoses of recombinant
human erythropoietin (rhEPO).1,2 Developing transcriptomics
methods is a promising approach to improve the sensitivity of the
hematological module of ABP. A number of studies have attempted to
characterize the transcriptomic blood signature after rhEPO
administration, and several genes have been identified as potential
RNA-based biomarkers.3,4 Among these, mRNAs encoding
5'-aminolevulinate synthase 2 (ALAS2), carbonic anhydrase 1 (CA1),
and solute carrier family 4 member 1 (SLC4A1) have been proposed as
candidates for the detection of blood manipulations. In earlier studies,
Salamin et al. and Loria et al. demonstrated that the expression of
these mRNAs increased following the administration of therapeutic
doses of rhEPO.5–7 Both the linear and the linear + circular forms of
ALAS2 mRNA (ALAS2 L and ALAS2 LC, respectively) may be useful as
potential biomarkers, as both were found to increase after therapeutic
injection of rhEPO.5 Circular mRNAs have a head and tail joined at
the splice site, rendering them more stable than linear mRNAs.8 This
propriety could be beneficial for monitoring RNA-based biomarkers in
the anti-doping context.
The large intraindividual variation in the expression of biomarkers
is problematic for the detection of blood doping using the ABP.
Environmental conditions such as altitude (hypoxia) can introduce an
additional challenge. Athletes often live or train at altitude to improve
their endurance,9 and hypoxia can affect the percentage of
reticulocytes (%RET) and the hemoglobin level, which are used by the
hematological module, resulting in ABP profiles suspicious for
doping.10–12
Furthermore, the official method recommended by the World
Anti-Doping Agency (WADA) for the collection of whole blood for
ABP analysis is venipuncture into ethylenediaminetetraacetic acid
(EDTA) tubes. However, this approach involves many obstacles
related to sample collection, transport, and storage.13 Thus, WADA
and different research groups have tested other matrices with the
aim of improving the logistics of sample handling. The use of dried
blood spots (DBSs), which are already used in pediatric science to
collect blood from newborns, could resolve some issues around
ABP sample handling.14 DBSs do not need to be collected by
trained medical personnel and can also be transported and stored
at room temperature.15 DBSs were already used in anti-doping
studies for detection of blood transfusion16 and direct detection of
rhEPO.17 Moreover, previous studies done by our group on RNA-
based biomarkers for indirect detection of rhEPO use demonstrate
that ALAS2 LC, ALAS2 L, CA1, and SLC4A1 mRNAs can be detected
using DBSs.5,6
The present study confirms that RNA-based biomarkers could
offer a viable solution for increasing the sensitivity and specificity of
the ABP. Furthermore, the method reported here provides a solution
for distinguishing between variations due to rhEPO use and variations
due to hypoxia exposure using DBSs as the matrix.
2 | MATERIALS AND METHODS
2.1 | Clinical study of rhEPO microdosing
Changes in RNA-based biomarkers after microdoses of rhEPO were
analyzed in DBS samples from a previous clinical study (ClinicalTrials.
gov, NCT04073849). Briefly, 21 healthy male athletes were blinded
and separated into two cohorts, rhEPO-treated group and control
group. In the first phase of the study, the treated participants received
eight injections of a boosting dose (40 IU/kg, s.c.) of rhEPO (epoetin
alfa, EPOGEN®, USA) over 20 days. In the second part of the study,
after a 10-day washout period, the rhEPO-treated subjects received
eight injections of an rhEPO microdose (900 IU, 13 IU/kg) over
12 days. Volunteers in the control group received injections of a saline
solution instead of rhEPO at the same delivery method and
frequency.
2.2 | Clinical study of hypoxia
In addition, samples from a controlled cross-over trial performed by
Voss et al.10 were used to monitor transcriptomic biomarkers under
hypoxic conditions. In brief, 10 healthy male athletes were separated
into two groups, altitude (ALT) and control (CON). For the ALT
protocol, volunteers were exposed to hypoxic conditions in altitude-
simulating rooms (14 days; 10 h per night at a simulated altitude of
3000 m and 6 h per day at a simulated altitude of 5400 m). Subjects
in the control group stayed in the same rooms, but the simulated
altitude remained at 250 m.
2.3 | RNA extraction and analysis
mRNA was extracted manually from DBSs and analyzed as described
by Loria et al.6 using the miRNeasy Mini Kit (Qiagen, Germany), fol-
lowing the manufacturer's instructions with minor modifications.5,6
After being cut from the collection card, the whole DBS was trans-
ferred into a 2-ml conical polypropylene microcentrifuge tube
(Eppendorf, Switzerland). The cells were lysed by adding 1-ml QIAzol
lysis reagent (Qiagen) to the tube and agitated (450 rpm) at 37C for
15 min. The tube was then sonicated (Sonicator S30®, Elmasonic®,
Germany) for 15 min and agitated again for 15 min under the same
conditions as in the first agitation step. Subsequently, chloroform
(250 μl) was added, and the sample was vortexed, incubated at room
temperature for 5 min, and then centrifuged for 15 min at 12,000  g
for 15 min. The aqueous phase (525 μl) was transferred to a new 2-ml
microcentrifuge tube and mixed with 800-μl ethanol and then trans-
ferred onto an RNeasy Mini spin column for washing. The extracted
RNA was eluted with 50-μl RNase-free water.
Transcriptomic biomarkers were analyzed by reverse
transcription-quantitative polymerase chain reaction (RT-qPCR).
Freshly extracted RNA was first reverse-transcribed into complemen-
tary DNA (cDNA) using the Transcriptor First Strand cDNA Synthesis
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Kit (Roche Life Science, Switzerland). The cDNA was diluted 1:10 in
H2O, and 4 μl of sample was loaded manually into 384-well plates
(Roche Life Science, Switzerland). A 6 μl of a primer mix consisting of
240-μl SYBR Green Master Mix (Qiagen) and 48 μl of primers
targeting the reference or target genes was added to wells with cDNA
samples. The primers were prepared by MicroSynth based on
sequences previously used by our group.5,6,18 All samples were ana-
lyzed in triplicate. The loaded plate was spin down at 2000 rpm for
2 min prior to RT-qPCR analysis on the LightCycler 480 System
(Roche Life Science) with the following cycles: 1 cycle of denaturation
10 min at 95C, 45 cycles of amplification 10 s at 95C and 1 min at
60C, and 1 cycle of melting curve 1 min at 55C and 5 s at 95C and
cooling down to 40C during 30 s. Results obtained for the target
mRNAs (ALAS2 LC, ALAS2 L, CA1, SLC4A1) were normalized using the
mean of the Cq values of three reference mRNAs (GAPDH, RGCC L,
and RGCC C). Results were analyzed using LightCycler software
(Version 1.5.0.39).
2.4 | ALAS2 and CA1 proteins measurement
ALAS2 and CA1 proteins were measured with respective ELISA
according to manufacturer's instructions (Human ALAS2 ELISA,
Abbexa Ltd., Switzerland) and (Human CA1 ELISA: LSBio, USA).
2.5 | Statistical analysis
To compare the %RET with values obtained by RT-qPCR for trans-
criptomic biomarkers, data were set to the percentage at baseline (%
baseline). The normality of the data was determined with the Shapiro
test. T-tests were used to compare differences between treated
(rhEPO and hypoxia) and nontreated samples. P < 0.05 was consid-
ered statistically significant. Statistical analyses were performed with
R software (R Studio Version 1.3.959).
3 | RESULTS
When compared with the baseline, the levels of ALAS2 LC, ALAS2 L,
CA1, and SLC4A1 mRNAs increased significantly after the rhEPO
boosting doses (Figure S1), which supports previously published find-
ings.5,6 In addition, the levels of ALAS2 LC, ALAS2 L, and CA1 mRNAs
were significantly higher after rhEPO microdosing (Figure 1). After
microdosing, the expression of ALAS2 LC mRNA increased by up to
300% from the baseline value at Day 35 and was significantly differ-
ent than the levels in the control group at multiple time points (D35,
P = 0.01; D37, P = 0.002; D39, P = 0.009; and D45, P = 0.01)
(Figure 1a). Similarly, rhEPO microdosing increased the level of ALAS2
L mRNA by up to 300% from the baseline value, with significant
F IGURE 1 The effects of rhEPO micro-doses on selected mRNA levels. The levels of ALAS2 LC (a), ALAS2 L (b), SLC4A1 (c), and CA1
(d) mRNAs in DBS samples after rhEPO (treated) or saline (control) microdosing, expressed as a percentage of the baseline values. *P < 0.05
versus control. The dashed lines indicate injections of rhEPO microdoses (900 IU)
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differences from the control group at D35 (P = 0.01), D37
(P = 0.004), D39 (P = 0.002), D43 (P = 0.005), D44 (P = 0.01), and
D45 (P = 0.009) (Figure 1b). The level of CA1 mRNA was also
increased by up to 300% after rhEPO microdosing, with significant
differences from the control group at D35 (P = 0.04), D37
(P = 0.009), D39 (P < 0.001), and D44 (P = 0.03) (Figure 1c). By con-
trast, the expression of SLC4A1 did not differ significantly between
the control and rhEPO microdosing groups. In the analysis, the range
of Cq values obtain during RT-qPCR are for GAPDH (24–28), RGCC L
(25–30), RGCC C (25–31), ALAS2 LC (22–30), ALAS2 L (22–30), CA1
(22–30), and SLC4A1 (26–31).
Next, the specificities and sensitivities of these potential RNA
biomarkers for the detection of rhEPO microdosing were investi-
gated. The ALAS2 LC mRNA level had a sensitivity of >50% when the
specificity was >95% and had an area under the curve (AUC) value of
0.75 (Figure 2a). For the ALAS2 L mRNA level, the sensitivity was
60% at a specificity of >95%, and the AUC value was 0.80
(Figure 2b), whereas the CA1 mRNA level had a sensitivity of >50%
at >95% specificity and an AUC value of 75% (Figure 2c). Finally, the
SLC4A1 mRNA level reached 50% sensitivity when the specificity
was <50%, and the AUC value was 0.54 (Figure 2d). Moreover, maxi-
mum individual increase after injection of microdoses was 450% for
ALAS2 LC, 400% for ALAS2 L, 350% for CA1, and 300% for SLC4A1
(Figure S2).
Finally, the effect of rhEPO on ALAS2 and CA1 protein expres-
sion was monitored in two subjects. Unlike the mRNA levels, the
ALAS2 and CA1 protein levels were not affected by the administra-
tion of rhEPO boosting doses (Figure S3).
Analyses of samples from the ALT and CON groups revealed that
hypoxia showed only a small and statistically insignificant effect on
the expression of ALAS2 LC, ALAS2 L, and SLC4A1 mRNAs (Figure 3a,
b,d). By contrast, the level of CA1 mRNA was significantly higher in
the ALT group compared with the CON group at D4 (P = 0.02) and
D7 (P = 0.007) (Figure 3c). Moreover, exposure to hypoxia had a sig-
nificant effect on the %RET, a component of the ABP (D7, P = 0.01)
(Figure 3e). Notably, this difference did not occur in the immature
fraction of RETs (IRF) (Figure 3f).
4 | DISCUSSION
The identification of rhEPO microdosing using the ABP is challenging
because microdoses do not induce significant changes in the %RET or
other hematological markers.2 Transcriptomic biomarkers are being
considered as a potential approach to increase the sensitivity of the
ABP. Previous studies have demonstrated that blood manipulations
and injection of rhEPO at therapeutic doses induce significant
increases in RNA-based biomarkers, including ALAS2 LC, ALAS2 L,
CA1, and SLC4A1 mRNAs.5–7 This current study confirmed these find-
ings by demonstrating significant increases in the levels of ALAS2 LC,
ALAS2 L, CA1, and SLC4A1 mRNAs after boosting doses of rhEPO.
Moreover, unlike the %RET,2 ALAS2 LC, ALAS2 L, and CA1 mRNA
F IGURE 2 The abilities of the RNA biomarkers to detect rhEPO micro-dosing. The sensitivities and specificities of ALAS2 LC (a), ALAS2 L (b),
CA1 (c), and SLC4A1 (d) mRNAs for the identification of rhEPO microdose injection (900 IU)
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levels were significantly elevated after rhEPO microdosing. Receiver
operating characteristic (ROC) curve analyses, which was carried out
to study the characteristics of the response of the selected, demon-
strated that these three RNA biomarkers had a specificity of >95%
with >50% sensitivity for the identification of rhEPO microdosing.
Moreover, AUC was higher than 0.75 and thus comparable to other
anti-doping markers.19,20 By contrast, SLC4A1 mRNA levels were not
significantly altered by microdosing, and an ROC curve analysis con-
firmed poor specificity at a sensitivity of ≥50% (Figure 2). Hypoxic
training performed under natural (altitude training) or artificial condi-
tions (hypoxic rooms with decreased oxygen content) is a legal way to
stimulate erythropoiesis in order to increase endurance performance.
It is frequently used by athletes and has been demonstrated to
increase the %RET, which makes hypoxia an important confounding
factor to be considered when interpreting hematologic ABP pro-
files.10–12 In fact, when only the %RET is used as a biomarker, it is dif-
ficult to differentiate between increases caused by hypoxia and those
caused by the abuse of rhEPO microdoses. The use of transcriptomic
biomarkers could improve the interpretation of hematologic profiles
in such a case. As demonstrated in this study, the magnitude of the
change in ALAS2 LC and ALAS2 L and CA1 mRNA expression after
rhEPO microdosing was up to 110% higher than the increase in
expression during hypoxic exposure, and the only mRNA that was sig-
nificantly affected by hypoxia was CA1. Moreover, when expression is
analyzed individually, it reaches peak to 450% for ALAS2 LC after
microdose administration (Figure S2). Furthermore, the analyses pres-
ented here were performed using DBSs, which were transported from
Salt Lake City (USA) and Doha (Qatar) to Lausanne (Switzerland) in an
envelope at room temperature. This ease of transport is one of the
advantages of DBSs for anti-doping analyses.15 The results presented
here indicate that DBSs could be used for transcriptomic5,6 or other
analyses (such as proteomic analyses) to detect biomarkers of blood
manipulations.16,21 The data from two volunteers demonstrated that,
unlike the expression of the corresponding mRNAs, the levels of
ALAS2 and CA1 protein were not affected by rhEPO boosting doses
(Figure S3). This may be because ALAS2 protein is present in all red
blood cells (RBC) and is found at particularly high concentrations
(mg/ml) in erythrocytes22; hence, detection of small variations may be
difficult, which is not the case of ALAS2 RNA present only in immature
RBC (RET and immature RET), which is a benefit for transcriptomic
markers. The level of protein has been measured using two specific
ELISA kits.
5 | LIMITATIONS
Regarding the application of the current results to routine, it has to be
noted that until now, all the samples used for this study were col-
lected from male volunteers who participated in the microdose study
and for which the results will be presented in the further summary of
the still ongoing project. Moreover, hypoxic conditions were simu-
lated in a hypoxic room, and a very high degree of hypoxia was
simulated in this study. Further limitation is also the lack samples after
hypoxic period, and only one samples has been collected 14 days
after hypoxic period. Based on these limitations, the next steps will be
to monitor variations in RNA-based biomarkers in women and to eval-
uate the effects of more natural hypoxic conditions on transcriptomic
markers using real altitude conditions and not hypoxia simulation
rooms. Additionally, the combined effects of rhEPO injection and hyp-
oxia on these novel markers will be evaluated, as has been done by
Bejder et al.12 for markers used in the hematological module of the
ABP. Moreover, reproducibility, standardization, and robustness of
the method will be tested in collaboration with other anti-doping lab-
oratories in future studies. Finally, direct detection on microdose
F IGURE 3 The effects of hypoxia on selected mRNA levels. The levels of ALAS2 LC (a), ALAS2 L (b), CA1 (c), and SLC4A1 (d) mRNAs in DBS
samples after hypoxia exposure, expressed as a percentage of the baseline values. *P < 0.05 versus CON group
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samples from Salt Lake City study could be of analytical interest and
fitness-for-purpose study using the recent published method.23,24 As
the near-future perspective, yet importantly, differences in ALAS2 LC
and ALAS2 kinetics that could be due to differences in posttranscrip-
tional modifications25 will be investigated.
In the future, ALAS2 mRNA-based biomarkers could be used to
create an alternative OFF-score in combination with hemoglobin
values to provide an additional tool to evaluate suspicious profiles.
Moreover, using DBSs for ALAS2 mRNA analysis allows samples to be
re-analyzed a long time after collection.
6 | CONCLUSION
In conclusion, this study demonstrates that transcriptomic biomarkers,
in particular ALAS2 mRNAs, could be used to improve the sensitivity
and specificity of the hematologic module of the ABP and are compat-
ible with the use of DBSs for anti-doping analyses. The expression of
SLC4A1 mRNA was increased by boosting/therapeutic doses
of rhEPO, but not microdoses, indicating that it is not a useful bio-
marker to detect microdosing. CA1 mRNA is an interesting candidate
biomarker, although, unlike ALAS2 mRNA, its expression also
increased significantly following exposure to hypoxia.
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